After pouring into biotech in 2Q, will generalists stay or will they go?

Investors believe generalists are likely to remain overweight in healthcare until there’s confidence that the broader economy can start to recover. When that will happen and whether some generalists might stick around even after recovery begins, are matters of debate.

The biggest dependency is the timing of an effective, broadly available COVID-19 vaccine, according to 13 buysiders interviewed by BioCentury...